Circulating Tumor Cells (CTC) in Lung Cancer

Launched by SHADIA JALAL · Dec 11, 2015

Keywords

ClinConnect Summary

This clinical trial is investigating the use of circulating tumor cells (CTCs) in patients with lung cancer. CTCs are cancer cells that have detached from a tumor and are found in the bloodstream. The main goal of the study is to create models using these cells to test new treatments that target DNA repair, which may help personalize therapy based on the specific mutations found in a patient’s CTCs. The trial is currently looking for participants who have advanced lung cancer, specifically those with stage 4 non-small cell lung cancer (NSCLC) or extensive-stage small cell lung cancer (SCLC), and who have not received any previous treatment for their advanced disease.

To be eligible, participants must be at least 18 years old and able to understand and sign a consent form. Both men and women from all backgrounds are welcome to join. Participants can expect to provide blood samples, either just once or several times, depending on their assigned group. This study could help improve treatment options for lung cancer patients by exploring how specific genetic changes in tumor cells can influence the effectiveness of new therapies.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria Cohort A (one-time blood sample) \& Cohort B (multiple blood samples)
• • Histologically or cytologically confirmed lung cancer (both non-small cell lung cancer and small cell lung cancer are allowed)
• • Stage 4 NSCLC or extensive-stage SCLC
• • Newly diagnosed disease with no prior systemic therapy for advanced disease Note: Patients that have received prior adjuvant chemotherapy or prior chemoradiotherapy for earlier stage lung cancer are allowed if treatment was completed ≥3 months.
• • Age ≥ 18 years
• • Ability to understand and the willingness to sign a written informed consent document
• • Inclusion of Women and Minorities Both men and women of all races and ethnic groups are eligible for this study.